Aperio Group LLC boosted its stake in shares of The Medicines Company (NASDAQ:MDCO) by 25.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,973 shares of the company’s stock after buying an additional 5,903 shares during the period. Aperio Group LLC’s holdings in The Medicines were worth $1,101,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. American Century Companies Inc. raised its position in shares of The Medicines by 4.7% in the first quarter. American Century Companies Inc. now owns 68,597 shares of the company’s stock valued at $3,354,000 after buying an additional 3,063 shares during the period. Advisors Asset Management Inc. raised its position in shares of The Medicines by 72.5% in the first quarter. Advisors Asset Management Inc. now owns 26,217 shares of the company’s stock valued at $1,282,000 after buying an additional 11,018 shares during the period. Tyers Asset Management LLC raised its position in shares of The Medicines by 12.4% in the first quarter. Tyers Asset Management LLC now owns 3,304 shares of the company’s stock valued at $162,000 after buying an additional 364 shares during the period. Great West Life Assurance Co. Can raised its position in shares of The Medicines by 8.7% in the first quarter. Great West Life Assurance Co. Can now owns 101,034 shares of the company’s stock valued at $4,938,000 after buying an additional 8,111 shares during the period. Finally, Whittier Trust Co. raised its position in shares of The Medicines by 5.2% in the first quarter. Whittier Trust Co. now owns 25,034 shares of the company’s stock valued at $1,224,000 after buying an additional 1,232 shares during the period.

Shares of The Medicines Company (NASDAQ MDCO) traded up 0.36% during trading on Wednesday, reaching $36.72. 247,295 shares of the company were exchanged. The Medicines Company has a 52-week low of $30.80 and a 52-week high of $55.95. The firm’s market cap is $2.64 billion. The stock’s 50-day moving average is $37.91 and its 200-day moving average is $44.66.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($5.52) earnings per share for the quarter, missing the consensus estimate of ($1.29) by $4.23. The Medicines had a negative net margin of 670.46% and a negative return on equity of 137.20%. The company had revenue of $18.74 million during the quarter, compared to the consensus estimate of $29.64 million. During the same period last year, the firm posted ($0.62) earnings per share. The company’s revenue for the quarter was down 65.8% on a year-over-year basis. Equities research analysts predict that The Medicines Company will post ($7.16) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “The Medicines Company (MDCO) Shares Bought by Aperio Group LLC” was published by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/the-medicines-company-mdco-shares-bought-by-aperio-group-llc/1496069.html.

Several equities analysts have recently issued reports on the stock. Cowen and Company boosted their price target on shares of The Medicines from $39.00 to $61.00 and gave the company an “outperform” rating in a report on Wednesday, April 19th. Oppenheimer Holdings, Inc. assumed coverage on shares of The Medicines in a report on Monday, May 22nd. They issued a “market perform” rating and a $50.00 price target for the company. ValuEngine lowered shares of The Medicines from a “sell” rating to a “strong sell” rating in a report on Saturday, May 20th. CIBC set a $50.00 price target on shares of The Medicines in a report on Tuesday, May 23rd. Finally, Citigroup Inc. boosted their price target on shares of The Medicines from $43.00 to $45.00 and gave the company a “neutral” rating in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $52.00.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with Analyst Ratings Network's FREE daily email newsletter.